TVRD · Insider Trading
Tvardi Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TVRD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | Michael S Wyzga | Director | A | +6,000 deriv. | — |
| 2026-06-11 | Susan Ph.D. Shiff | Director | A | +6,000 deriv. | — |
| 2026-06-11 | Sujal Shah | Director | A | +6,000 deriv. | — |
| 2026-06-11 | Cynthia Smith | Director | A | +6,000 deriv. | — |
| 2026-06-11 | Wallace L Hall Jr | Director | A | +6,000 deriv. | — |
| 2026-02-02 | Stephen Paul O'Brien | Principal Accounting Officer | A | +15,000 deriv. | — |
| 2026-02-02 | Avi Daniel Conn | Chief Financial Officer | A | +45,000 deriv. | — |
| 2026-02-02 | John Saewook M.D. Kauh | Chief Medical Officer | A | +45,000 deriv. | — |
| 2026-02-02 | Imran Nizamudin Alibhai | Chief Executive Officer | A | +115,000 deriv. | — |
| 2025-12-18 | Avi Daniel Conn | Chief Financial Officer | A | +17,500 deriv. | — |
| 2025-12-18 | Imran Nizamudin Alibhai | Chief Executive Officer | A | +47,500 deriv. | — |
| 2025-12-18 | Stephen Paul O'Brien | Principal Accounting Officer | A | +4,000 deriv. | — |
| 2025-12-18 | John Saewook M.D. Kauh | Chief Medical Officer | A | +17,500 deriv. | — |
| 2025-08-05 | Samuel David Tweardy | 10%+ Owner | J | −315,658 | — |
| 2025-05-02 | Shaheen Wirk | Director | A | +439,194 | — |
| 2025-05-02 | Wallace L Hall Jr | Director | A | +246,756 | — |
| 2025-04-21 | Jeffrey Leroy Larson | SVP, Research & Development | A | +10,820 deriv. | — |
| 2025-04-21 | Avi Daniel Conn | Chief Financial Officer | A | +43,547 deriv. | — |
| 2025-04-21 | Imran Nizamudin Alibhai | Chief Executive Officer | A | +182,320 deriv. | — |
| 2025-04-21 | Yixin Chen | VP, Chem, Mfg and Ctrls | A | +7,213 deriv. | — |
| 2025-04-21 | Stephen Paul O'Brien | Principal Accounting Officer | A | +7,213 deriv. | — |
| 2025-04-21 | Cynthia Smith | Director | A | +12,000 deriv. | — |
| 2025-04-21 | John Saewook M.D. Kauh | Chief Medical Officer | A | +36,210 deriv. | — |
| 2025-04-21 | Michael S Wyzga | Director | A | +12,000 deriv. | — |
| 2025-04-21 | Susan Ph.D. Shiff | Director | A | +12,000 deriv. | — |
| 2025-04-21 | Wallace L Hall Jr | Director | A | +12,000 deriv. | — |
| 2025-04-21 | Shaheen Wirk | Director | A | +12,000 deriv. | — |
| 2025-04-21 | Sujal Shah | Director | A | +12,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Shaheen Wirk | Director | 263,164 | $221.61K |
| Wallace L Hall Jr | Director | 202,044 | $170.14K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TVRD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.